Developments in the pharmacokinetic/pharmacodynamic index of linezolid: A step toward dose optimization using Monte Carlo simulation in critically ill patients

International Journal of Infectious Diseases

Volumn 22, Issue , 2014, Pages 35-40

  Dong, Haiyan ^a   Xie, Jiao ^a   Chen, Lihong ^a   Wang, Taotao ^a   Sun, Jinyue ^a   Zhao, Yingren ^a   Dong, Yalin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Critically ill patients; Dose optimization; Linezolid; Monte carlo simulation; Pharmacokinetic pharmacodynamic (PK PD)

Indexed keywords

LINEZOLID; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG EFFICACY; ENTEROCOCCUS FAECALIS; HUMAN; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PLASMA CONCENTRATION-TIME CURVE; STAPHYLOCOCCUS SAPROPHYTICUS; STREPTOCOCCUS CONSTELLATUS; BLOOD; COMPUTER SIMULATION; CRITICAL ILLNESS; DOSE CALCULATION; DRUG EFFECTS; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PHYSIOLOGY; STATISTICAL MODEL; STREPTOCOCCUS PNEUMONIAE;

ACETAMIDES; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; COMPUTER SIMULATION; CRITICAL ILLNESS; DRUG DOSAGE CALCULATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; MONTE CARLO METHOD; OXAZOLIDINONES; STREPTOCOCCUS PNEUMONIAE;

EID: 84897068063     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2014.01.016     Document Type: Article

References (23)

1. Woodford N., Livermore D.M. Infections caused by Gram-positive bacteria: a review of the global challenge. J Infection 2009, 59:S4-S16.
2. Vinh D.C., Rubinstein E. Linezolid: a review of safety and tolerability. J Infection 2009, 59:S59-S74.
3. Rubinstein E., Isturiz R., Standiford H.C., Smith L.G., Oliphant T.H., Cammarata S., et al. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother 2003, 47:1824-1831.
4. Mutnick A.H., Enne V., Jones R.N. Linezolid resistance since 2001: SENTRY antimicrobial surveillance program. Ann Pharmacother 2003, 37:769-774.
5. Rahim S., Pillai S.K., Gold H.S., Venkataraman L., Inglima K., Press R.A. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin Infect Dis 2003, 36:e146-e148.
6. Scheetz M.H., Knechtel S.A., Malczynski M., Postelnick M.J., Qi C. Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption. Antimicrob Agents Chemother 2008, 52:2256-2259.
7. Mulanovich V.E., Huband M.D., McCurdy S.P., Lemmon M.M., Lescoe M., Jiang Y., et al. Emergence of linezolid-resistant coagulase-negative Staphylococcus in a cancer centre linked to increased linezolid utilization. J Antimicrob Chemother 2010, 65:2001-2004.
8. Thallinger C., Buerger C., Plock N., Kljucar S., Wuenscher S., Sauermann R., et al. Effect of severity of sepsis on tissue concentrations of linezolid. J Antimicrob Chemother 2008, 61:173-176.
9. Dong H., Wang X., Dong Y., Lei Je, Li H., You H., et al. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients. Int J Antimicrob Agents 2011, 38:296-300.
10. Bhattaram V., Bonapace C., Chilukuri D., Duan J., Garnett C., Gobburu J., et al. Impact of pharmacometric reviews on new drug approval and labeling decisions-a survey of 31 new drug applications submitted between 2005 and 2006. Clin Pharmacol Ther 2007, 81:213-221.
11. Nielsen E.I., Cars O., Friberg L.E. Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Antimicrob Agents Chemother 2011, 55:4619-4630.
12. Adembri C., Novelli A. Pharmacokinetic and pharmacodynamic parameters of antimicrobials: potential for providing dosing regimens that are less vulnerable to resistance. Clin Pharmacokinet 2009, 48:517-528.
13. Roberts J.A., Kirkpatrick C.M., Lipman J. Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J Antimicrob Chemother 2011, 66:227-231.
14. Mouton J.W., Dudley M.N., Cars O., Derendorf H., Drusano G.L. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005, 55:601-607.
15. Rayner C.R., Forrest A., Meagher A.K., Birmingham M.C., Schentag J.J. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003, 42:1411-1423.
16. Mouton J.W., Dudley M.N., Cars O., Derendorf H., Drusano G.L. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents 2002, 19:355-358.
17. Maglio D., Kuti J.L., Nicolau D.P. Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program. Clin Ther 2005, 27:1032-1042.
18. Petrosillo N., Drapeau C., Agrafiotis M., Falagas M. Some current issues in the pharmacokinetics/pharmacodynamics of antimicrobials in intensive care. Minerva Anestesiol 2010, 76:509-524.
19. Roberts J.A., Lipman J. Antibacterial dosing in intensive care. Clin Pharmacokinet 2006, 45:755-773.
20. Roberts J.A., Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009, 37:840-851.
21. Saner F.H., Heuer M., Rath P.M., Gensicke J., Radtke A., Drühe N., et al. Successful salvage therapy with tigecycline after linezolid failure in a liver transplant recipient with MRSA pneumonia. Liver Transplant 2006, 12:1689-1692.
22. Webster D.P., Griffiths S., Bowler I.C. Failure of linezolid therapy for post-neurosurgical meningitis due to Enterococcus faecium. J Antimicrob Chemother 2009, 63:622-623.
23. Asín E., Isla A., Canut A., Rodríguez Gascón A. Comparison of antimicrobial pharmacokinetic/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria. Int J Antimicrob Agents 2012, 40:313-322.